The neuroinvasive potential of the Severe Acute Respiratory Syndrome novel coronavirus, SARS-CoV-2, is being recognized, with enhanced awareness that the associated infection, Coronavirus Diseases 2019 (COVID-19), might result in neurological injury. Indeed, there is a growing body of evidence to suggest that a subset of COVID-19 patients will experience neurological manifestations of the infection [1]. Since genomic studies show that the SARS-CoV-2 virus has similar homological sequences with two of its beta-coronavirus predecessors, the SARS-CoV associated with Severe Acute Respiratory Syndrome (SARS) [2] and the virus associated with Middle Eastern Respiratory Syndrome (MERS) [3], it is helpful to review the neurological symptoms of these two earlier diseases as the plausible link between COVID-19 and neurological symptoms are explored. Furthermore, the pathophysiological pathways of these three conditions (COVID-19, SARS, and MERS) might be expected to be similar [4–6]. Neurotropism has been observed in both MERS and SARS [7–9], and there are early findings of certain neurological manifestations in COVID-19 patients [4,10]. The RNA of the SARS-CoV-2 virus has been identified in the cerebrospinal fluid of a COVID-19 patient, demonstrating its neurotropic potential. It is clinically relevant to determine how the SARS-CoV-2 virus can access the central nervous system (CNS) and whether the neuronal injury caused by the virus might be connected to the injury of the autonomic nervous system.